with autoimmune phenomena, immunomodulators such as interferon (5) (6) (7) or other immunosuppressor drugs such as cyclosporine (8, 9) and corticoids (10, 11) have been reported to be active against the disease in simple case reports or in very small series. Indeed, the vast majority of reports dealing with this condition are simple case reports treated with single agents or conventional chemotherapy regimes typically used against aggressive lymphomas. However, taking into account the dismal prognosis of the disease, conventional chemotherapy regimes have been tested, generally with unsatisfactory results (11) (12) (13) (14) (15) (16) (17) (18) .
Following initial reports of the favourable impact of high dose chemotherapy/autologous stem cell therapy (HDC/ASCT), the European Group for Bone Marrow Transplantation (EBMT) reported a 5-yr event-free survival (EFS) of 37% and an overall survival (OS) of 44% at 5 yr in 29 patients, of whom 14 underwent transplantation as a first line therapy (19) . As a further contribution to redress the lack of data regarding therapeutic measures for this condition, we report here our experiences with 19 patients treated with HDC/ASCT within the GELTAMO Spanish lymphoma group.
Patients and methods

Patients
Between 1992 and 2004, 19 patients with AIL who underwent HDC/ASCT were reported to the GELTAMO registry. The clinical characteristics of the patients at diagnosis are shown in Table 1 . The median age at transplantation was 46 yr, and 15 patients were transplanted as front line therapy having been judged by their primary physician to have high risk factors of failure. Of these 15 patients, eight were transplanted as a consolidation of the first complete response (CR), five patients were transplanted in the first partial response (PR), and two patients were transplanted in a primary refractory disease state. Four patients received the transplant as a salvage therapy, of which three patients were in a second or third CR phase and one patient in the second PR (Table 2) .
Standard criteria to determine eligibility for therapy were applied including: bilirubin levels <2 mg/dL; creatinine levels <1.5 mg/dL; an ejection fraction >50%; and appropriate diffusing lung tests >50% of the predictive value. Histological diagnosis was established by the pathologist in each centre. Cases that displayed difficult diagnostic features were referred to an expert haematopathologist following the recommendations of the group.
The disease stage was evaluated according to the Ann Arbour staging system and patients were staged according to standard procedures through: physical examination; blood and serum assays; chest X-rays; and computed tomography of the neck, chest, abdomen and pelvis. Bone marrow aspirates and biopsies were obtained prior to HDC and other staging criteria were assessed at (20) and other variables of known prognostic importance in this type of lymphomas were also evaluated (21) (22) (23) . The details and factors associated with transplantation are provided in Table 2 .
Response and follow-up criteria
The response to therapy was evaluated by the investigator responsible in each centre at 1, 3 and 6 months post-transplantation, and every 6 months thereafter. Evaluations followed standard guidelines (24), carrying out a physical examination, complete blood counts, serum biochemistry, bone marrow aspiration and biopsy, and radiological studies as mentioned above. CR was defined as the disappearance of all clinical evidence of lymphoma for a minimum of 4 wk with no persistence of symptoms related to the disease. Prior to transplantation, a complete restaging was established in all patients. To categorize a patient with a CR after HDC/ASCT, residual masses had to remain unchanged for 6 months or longer. A PR was defined as a decrease of more than 50% in the sum of the two longest diameters of all measurable lesions over at least 4 wk and non-measurable lesions had to decrease by at least 50%. In this category, no lesions increased in size and no new lesions appeared. Progressive disease (PD) was defined as any increase of more than 25% in the sum of the diameter of any measurable lesions or the appearance of a new lesion. Transplant-related mortality (TRM) was defined as death within 100 d of HDC/ASCT not related to the disease, relapse or progression. Toxic mortality was considered at any time, if it was related to the therapeutic procedure.
Statistical methods
Progression-free survival (PFS) and OS were measured from the date of transplantation and were estimated according to the Kaplan-Meier method (25) . Comparisons amongst the variables of interest were performed by the log-rank test (26) . All P-values reported were twosided and the statistical significance was defined at a P-value < 0.05.
Results
Outcome
Post-transplantation, 79% of the whole population could be considered to have achieved a CR (n ¼ 15), while 5% of patients displayed a PR (n ¼ 1) and the procedure failed in 16% (n ¼ 3, including the two cases transplanted in a refractory disease state). Table 3 shows response to transplant considering the disease status before transplant. With a median observation time in living patients of 25 months (9-151), the OS at 3 yr was 60% (95% CI: 37-83) and the PFS was 55% (95%, CI: 31-79; Fig. 1 ).
To date, eight patients had died, seven of them due to the disease and one patient from a second neoplasia (MDS). There were no incidences of TRM or toxic deaths related to procedure.
Prognostic factors
Despite being a small group of patients, we performed a univariate analysis to determine which clinical factors 
Months from transplantation
Treatment of AIL with HDC/ASCT
Rodríguez et al.
might be associated with the outcome. The group of eight patients transplanted in the first CR had an OS and PFS at 3 yr of 56%. Similarly, no differences were observed in the OS or PFS at 3 yr amongst the group of 15 patients transplanted as a front line therapy when compared with the four patients who were transplanted at relapse (67% vs. 50%, P ¼ 0.29 and 59% vs. 50%, P ¼ 0.57 respectively). However, the refractory disease state at transplantation that was observed in two patients, predicted a dismal prognosis as both these patients died from the disease shortly after the procedure (within 1 and 3 months). Likewise, patients with extranodal disease at the time of transplantation and with bone marrow involvement were associated with a poor outcome. Between the prognostic indexes studied the outcome was significantly associated with the a-IPI, Pretransplant Peripheral T-cell lymphoma Score (PPS) (23) and Prognostic Index for peripheral T-cell lymphoma (PIT) (22) ( Table 4 , Fig. 2 ).
Discussion AIL is a rare disease with a poor prognosis. With the therapeutic strategies currently available, a median survival of 18-36 months has been observed when conventional chemotherapy was applied in most series (4, 12) . There is a lack of informative series of patients that have been treated uniformly and indeed, most reports include single patients or very small groups of patients. Therefore, it is difficult to draw firm conclusions from the information obtained to date. Recently, the EBMT reported their experiences with 29 patients diagnosed with this disease and subjected to HDC/ASCT. Half of the patients received the transplant as part of a first-line therapy and half as second or third line therapy (19) . This group reported a CR of 76% after HDC/ASCT, which is similar to the CR in our series (79%). Along similar lines, the 5-yr OS and PFS were 44% and 37% respectively, inferior to our 60% and 55% OS and PFS at 3-5 yr respectively. However, this may reflect the fact that most of our patients (79%) were transplanted as a first line treatment as opposed to 45% in the EBMT series. Furthermore, our median observation period of 25 months for surviving patients is shorter than the 60 months in the EBMT series. Our analysis showed that like patients with other aggressive Peripheral T-cell lymphoma (PTCL), those transplanted in a refractory disease state do poorly with HDC/ASCT (27) (28) (29) . In addition, we found that the presence of extranodal disease (bone marrow) or more than one adverse factor at transplant of those assessed in the a-IPI, PPS or PIT scores was associated with a worse outcome. Although studied in few patients, this information suggests that HDC/ASCT improves the outcome of the disease when compared with conventional treatment, indicating that prospective studies to test this therapeutic modality are necessary. Moreover, the use of this therapy is limited in the elderly population. Therefore, taking into account the biological phenomena associated with the disease, novel more specific therapies will be needed and other potential targets must be defined. Interestingly, immunomodulatory and antiangiogenic agents have been reported to have positive impact on the disease (IFNa, IL-2, Thalidomide...), however the real impact of these agents remains unknown due to the small number of patients studied (4, 30) . Another intriguing approach that involves targeting the B-cell component rather than the malignant T-cell population is currently being tested (31) . Indeed, this Bcell component is responsible for several features of the disease and it is argued that it may contribute to sustain the malignant T cells. Along similar lines, there are several reports outlining the responses to Rituximab in treating this disease. Furthermore, a certain efficacy has also been reported with Campath-1H in single case reports (32) . Thus, new biological agents, used either individually or in combination with conventional chemotherapy may have an impact on the disease. However, as suggested by our data and that of others ASCT, may represent the best available consolidation therapy for patients that comply with certain criteria.
In conclusion, our data show that HDC/ASCT offers better results than conventional chemotherapy in treating aggressive lymphomas. Although further follow-up is needed to confirm these results, more than half of the patients in this study were in continued remission. However, we identified several factors such as refractory disease state, extranodal disease (bone marrow involvement) and the presence of more than one adverse factor from the a-IPI, PPS or PIT pretransplantation scores that are unfavourable factors associated with a poor outcome of this therapeutic modality. New target therapies drawn from genomic and proteomic studies should be defined in order to develop more specific therapies. Moreover, due to the rarity of the disease, cooperative efforts and well-designed prospective studies are needed in order to reach meaningful conclusions.
